BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Bristol Myers Squibb advances US manufacturing investment with new $2.3 B campus

August 11, 2026 | News

New state-of-the-art facility will create nearly 500 skilled jobs and accelerate the delivery of next-generation medicines



Bristol Myers Squibb (BMS) has announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients.

The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.

The selection of Houston marks a significant milestone in BMS' $40 billion commitment to invest in the United States (US) over five years across research and development, technology and domestic manufacturing.

Its modular design allows BMS to add and reconfigure manufacturing capacity as needed, reflecting BMS' current and future pipeline. Its multi-modal capabilities allow BMS to manufacture multiple types of medicines - such as small molecules, biologics, and antibody-drug conjugates - across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch. This flexibility ensures the campus can evolve to meet patient needs well into the future.